Fate Therapeutics Inc (FATE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.74M
Last updated: Nov 17, 2026 at 11:06 AM ET
Fate Therapeutics Inc (FATE) Competitors
The companies most similar to Fate Therapeutics are Lineage Cell Therapeutics (LCTX), Protara Therapeutics (TARA) and Invivyd (IVVD). By market cap, Fate Therapeutics ranks 7th of the 13 companies on this page; Fulcrum Therapeutics (FULC) is the largest at $287.96M.
Peer Comparison
FATE's ROIC of -51.3% is above the peer median of -74.1%, and its revenue growth of 9.2% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Fate Therapeutics (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Lineage Cell Therapeutics Inc (LCTX) | $231.35M | N/A | 18.7x | 16.2% | -6.7% | -61.0% | 0.00% |
| Protara Therapeutics Inc (TARA) | $155.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Armata Pharmaceuticals Inc (ARMP) | $143.94M | N/A | 14.7x | 0.0% | -184.6% | 173.6% | 0.00% |
| Foghorn Therapeutics Inc (FHTX) | $124.12M | 40.1x | 1.1x | 8.4% | N/A | 925.0% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| Sutro Biopharma (STRO) | $163.03M | N/A | 3.4x | 0.0% | N/A | -6.1% | 0.00% |
| OUTLOOK THERAPEUTICS INC (OTLK) | $100.54M | N/A | N/A | 0.0% | -776.9% | -99.4% | 0.00% |
| Bicycle Therapeutics Ltd (BCYC) | $236.22M | N/A | 2.7x | -169.8% | N/A | 190.2% | 0.00% |
| Peer median | $154.96M | 40.1x | 3.1x | 0.0% | -74.1% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Fate Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Lineage Cell Therapeutics Inc (LCTX) | Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment... | LCTX competitors |
| Protara Therapeutics Inc (TARA) | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment... | TARA competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Armata Pharmaceuticals Inc (ARMP) | Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment... | ARMP competitors |
| Foghorn Therapeutics Inc (FHTX) | Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within... | FHTX competitors |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| Sutro Biopharma (STRO) | Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. | STRO competitors |
| OUTLOOK THERAPEUTICS INC (OTLK) | Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic... | OTLK competitors |
| Bicycle Therapeutics Ltd (BCYC) | Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. | BCYC competitors |
Frequently Asked Questions About FATE
Who are Fate Therapeutics' main competitors?
The companies most similar to Fate Therapeutics include Lineage Cell Therapeutics (LCTX), Protara Therapeutics (TARA), Invivyd (IVVD), Compass Therapeutics (CMPX) and Fulcrum Therapeutics (FULC), listed from the closest match.
Who is Fate Therapeutics' biggest competitor?
Fulcrum Therapeutics (FULC) is the largest of the similar companies at $287.96M; Lineage Cell Therapeutics (LCTX) is the closest match by business profile, size, sector and industry.
How does FATE stock compare with its competitors?
FATE's P/S is 29.7x against a peer median of 3.1x; its net margin is 0.0% against a peer median of 0.0%.
Which of Fate Therapeutics' competitors pays a higher dividend?
Fate Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Fate Therapeutics bigger than its competitors?
No. Fate Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Fulcrum Therapeutics (FULC) at $287.96M.
FATE pages: Overview, Earnings, Forecast, Financials, Competitors